Real-World study tracks lung cancer drug Osimertinib's effectiveness over 3 years
NCT ID NCT05103605
First seen Dec 08, 2025 · Last updated May 14, 2026 · Updated 18 times
Summary
This study observes 274 adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It looks at how doctors use the drug osimertinib as the first treatment and how patients do over 36 months, including survival and quality of life. The goal is to understand the drug's real-world effectiveness, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Abbeville, France
-
Research Site
Aix-en-Provence, France
-
Research Site
Angers, France
-
Research Site
Antibes, France
-
Research Site
Avignon, France
-
Research Site
Bastia, France
-
Research Site
Bayonne, France
-
Research Site
Bordeaux, France
-
Research Site
Bourg-en-Bresse, France
-
Research Site
Brest, France
-
Research Site
Cannes, France
-
Research Site
Chambéry, France
-
Research Site
Chauny, France
-
Research Site
Cholet, France
-
Research Site
Clermont-Ferrand, France
-
Research Site
Colmar, France
-
Research Site
Contamine-sur-Arve, France
-
Research Site
Créteil, France
-
Research Site
Elbeuf, France
-
Research Site
Epagny METZ Tessy, France
-
Research Site
Évreux, France
-
Research Site
La Roche-sur-Yon, France
-
Research Site
Libourne, France
-
Research Site
Limoges, France
-
Research Site
Lyon, France
-
Research Site
Marseille, France
-
Research Site
Meaux, France
-
Research Site
Mulhouse, France
-
Research Site
Orléans, France
-
Research Site
Paris, France
-
Research Site
Poitiers, France
-
Research Site
Quimper, France
-
Research Site
Reims, France
-
Research Site
Rouen, France
-
Research Site
Saint-Denis, France
-
Research Site
Saint-Grégoire, France
-
Research Site
Saint-Pierre, France
-
Research Site
Saint-Priest-en-Jarez, France
-
Research Site
Saint-Quentin, France
-
Research Site
Toulon, France
-
Research Site
Toulouse, France
-
Research Site
Valenciennes, France
-
Research Site
Vannes, France
-
Research Site
Villefranche-sur-Saône, France
-
Research Site
Villenave-dornon, France
-
Research Site
Villeurbanne, France
Conditions
Explore the condition pages connected to this study.